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Abstract
Because of the low overall response rates of 10–47% to targeted cancer therapeutics, there is an increasing need for
predictive biomarkers. We aimed to identify genes predicting response to five already approved tyrosine kinase inhibitors.
We tested 45 cancer cell lines for sensitivity to sunitinib, erlotinib, lapatinib, sorafenib and gefitinib at the clinically
administered doses. A resistance matrix was determined, and gene expression profiles of the subsets of resistant vs.
sensitive cell lines were compared. Triplicate gene expression signatures were obtained from the caArray project.
Significance analysis of microarrays and rank products were applied for feature selection. Ninety-five genes were also
measured by RT-PCR. In case of four sunitinib resistance associated genes, the results were validated in clinical samples by
immunohistochemistry. A list of 63 top genes associated with resistance against the five tyrosine kinase inhibitors was
identified. Quantitative RT-PCR analysis confirmed 45 of 63 genes identified by microarray analysis. Only two genes (ANXA3
and RAB25) were related to sensitivity against more than three inhibitors. The immunohistochemical analysis of sunitinib-
treated metastatic renal cell carcinomas confirmed the correlation between RAB17, LGALS8, and EPCAM and overall survival.
In summary, we determined predictive biomarkers for five tyrosine kinase inhibitors, and validated sunitinib resistance
biomarkers by immunohistochemistry in an independent patient cohort.
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Introduction
Targeted therapy in cancer treatment refers to the application
of special agents acting on specific molecular features of signal
transduction pathways involved in the development of the
cancerous phenotype. Erlotinib, gefitinib, sorafenib, sunitinib
and lapatinib are all clinically used tyrosine kinase inhibitors
(TKIs) targeting receptors and downstream members of the
ERBB/RAS pathway [1]. Erlotinib and gefitinib are reversible
epidermal growth factor receptor (EGFR) tyrosine kinase inhib-
itors used in the treatment of non-small cell lung cancer. About
10% of the patients respond to the treatment in the European and
Northern American population [2]. Lapatinib inhibits the tyrosine
kinase domain of the epidermal growth factor receptor (EGFR)
and human epidermal growth factor receptor 2 (HER2). It is
approved for the treatment of breast cancer, where the overall
response rate to this treatment is 24% [3]. Sorafenib inhibits RAF,
VEGFR, PDGFR, Flt-3, c-Kit receptors. The partial response rate
is 10%, when it is administered for patients with advanced renal-
cell carcinoma [4]. Sunitinib is a small-molecule multi-targeted
receptor tyrosine kinase (RTK) inhibitor that was approved by the
FDA for the treatment of renal cell carcinoma (RCC) and
imatinib-resistant gastrointestinal stromal tumor (GIST). Objective
response rate is 31% in the first line treatment of renal cell
carcinoma [5]. Because of the low overall response rates of 10–
47% [6–10], there is an increasing need for biomarkers predicting
response to targeted therapy treatment.
Besides pharmacokinetic parameters, a tumor can deploy
different molecular mechanisms to achieve resistance against
targeted therapy agents: the target molecule may be subject to
modification, downstream alterations of the pathway may lead to
resistance against an agent targeting an upstream molecule, or
other pathways may be activated which alternatively mediate
cancer cell survival and proliferation. For example, the T790M
mutation of the EGFR gene retains the ability of the receptor to
activate the downstream pathway but simultaneously decreases
binding of gefitinib and erlotinib to the receptor and thus leads to
drug resistance [11]. MET amplification causes resistance against
erlotinib and gefitinib through the activation of alternative
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pathways [12]. Interleukine-8 can activate an alternative pathway
leading to sunitinib resistance [13]. Mutations of the genes of
downstream members of the pathway can also contribute to
resistance against targeted therapy agents, as described before in
case of KRAS [14], PTEN [15], BRAF [16], and PIK3CA [17].
When a downstream component of the signaling system activates
the pathway, inhibition by the blockade of an upstream member
was shown to be ineffective. These downstream changes can be
used as negative predictors for agents acting upstream of this
addictive element of the pathway, as described before for KRAS
[18]. If KRAS harbors an activating mutation, agents acting on
EGFR will not have any effect on tumor growth [19].
Previous studies have already described that the use of gene
expression data, coupled with in vitro drug sensitivity assays, can be
used to develop signatures that could classify response to
conventional anticancer agents [20,21]. In another study, a panel
of cancer cell lines was treated with dasatinib, a multitarget kinase
inhibitor, and sensitivity to the drug was measured. In parallel,
expression data generated from the same panel of cell lines was
used to develop a signature to predict sensitivity to the drug [22].
In a different study, a panel of lung cancer cell lines was used to
develop gene expression signatures that predict sensitivity to the
EGFR inhibitors gefitnib [23] and erlotinib [24]. Finally, the
common significant genes of an in vitro and an in vivo study were
able to predict response to rapamycin [25]. Although focused on
single therapeutic agents in one type of cancer, these studies
already demonstrated the power of gene expression profiles to
predict response to a specific agent.
In this present study, we took a broader approach aiming to
identify gene signatures associated with intrinsic resistance against
5 already approved tyrosine kinase inhibitors targeting the ERBB/
RAS-pathway. To obtain new predictive biomarkers, we corre-
lated the sensitivity of 45 cell lines representing 15 different cancer
entities to expression patterns. The best performing candidate
genes were then validated using qRT-PCR. Finally, clinical
validation was performed using immunohistochemistry based on
tissue microarrays on a set of renal cell carcinomas from patients
treated with sunitinib.
Materials and Methods
Ethics Statement
The approval number for the sample collection by the National
Scientific and Research Ethics Committee (ETT-TUKEB)
(Hungary) is #185/2007. General informed consent was obtained
before the surgery. The National Scientific and Research Ethics
Committee did not request a specific written permission, because,
it was a retrospective study, and the patients were handled
anonymously.
Cell Culture
We obtained 45 ATCC cell lines. Before selection, the absence
of KRAS mutation in the cell lines was confirmed using the
Catalogue of Somatic Mutations in Cancer (search done on the
25th of June 2010). The cells were cultured according to the
ATCC protocols (http://www.lgcstandards-atcc.org/). Addition-
ally, antibiotics (Penicillin-streptomycin, Invitrogen, cat. no.:
15070-063, Amphotericin B, Invitrogen, cat. no.: 15290-026)
were added. The cell lines are summarized in Table 1. An
overview of the study is presented in Figure 1.
DNA Isolation and Quality Control
DNA was isolated using the Qiagen DNeasy Blood and Tissue
Kit (Qiagen, Hilden, Germany, cat. no.: 69506) according to the
product user’s guide. Quantity and quality of the DNA were tested
by using a Nanodrop 1000 system (BCM, Houston, TX, USA).
DNA (A260) and protein (A280) concentrations and sample purity
(260/280 ratio) were measured and only high quality DNA was
used for further analysis. DNA was stored at 280uC.
Authentication of Cell Lines
Authentication was performed for cell lines obtained more than
4 years ago from ATCC using short tandem repeat (STR) analysis
of 10 specific loci in the human genome and a mouse specific
marker. Authentication was carried out by StemElite ID System at
the Fragment Analysis Facility, Johns Hopkins University
(Baltimore, USA). STR profiles of the applied cell lines were
compared to the STR profile database of the Leibniz Institute
DSMZ - German Collection of Microorganisms and Cell Cultures
(http://www.dsmz.de). All cell lines included in this study were
contamination-free.
Resistance Tests
Drugs were used in their commercially available form, and were
applied to the cells in 3 concentrations (C1, C2, C3). C1=0.1*C2
and C3= 10*C2. Concentration C2 was deduced from the
clinically used doses (see Table 2).
The MTT assay (Roche, Cat. No.: 11465007001), was used to
test the anti-proliferative effect of reagents and cell viability. In
each experiment, 2000 cells/well were seeded in 100 ml medium
onto 96-well plates. After one day incubation, precontrol cells were
stained. At the same time, the cultures were treated with all 5
studied drugs at C1, C2 and C3 concentrations. On the fifth day
the experiment was terminated and the cells were stained. The
absorbance was read with a Thermo Scientific MultiskanH FC.
The absorbance measured at 595 nm was corrected with the
background measured at 690 nm. All measurements were
repeated three times and for the calculation of the resistance
index (RI) values, the averages of the 3 measurements were used.
The resistance index (RI) was computed by the formula [26]:
RI~
N2{Npre
Npost{Npre
,
where Npre is the medium absorbance value of precontrol
(representing the number of cells at the beginning of the
treatment), Npost is the medium absorbance value of control
(representing the number of cells at the end of the treatment with
vehicle treatment only), and N2 is the medium absorbance value of
treated cells treated with the C2 concentration of the studied drug.
C1 and C3 concentrations were used as internal controls to
monitor the dynamic range of the agents. Only cell lines that
fulfilled the quality criteria of Npost.Npre and deviation in cell
growth within repetitions ,15% were included in the evaluation.
Feature Selection
Raw microarray data for the cell lines were generated in the
GSK caArray project (ftp://caftpd.nci.nih.gov/pub/caARRAY/
transcript_profiling). caArray was developed using the caBIG
compatibility guidelines, as well as the Microarray Gene
Expression Data (MGED) society standards for microarray data.
After downloading, the raw.CEL files were MAS5 normalized in
the R statistical environment (www.r-project.org) using the affy
Bioconductor library [27]. MAS5 ranked among the best
normalization methods when compared to the results of qRT-
PCR measurements in our recent study [28]. Each cell line was
measured on the microarrays by triplicates - in the final step of the
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Table 1. Resistance characteristics of the 45 cell lines investigated.
Cell line Origin ATCC lapatinib erlotinib sorafenib sunitinib gefitinib
CCRF-CEM ALL CCL-119 SW-948 0,26 NCI-H441 20,11 NCI-H69 21,53 A-375 20,15 Hep-3B 20,09
MOLT-4 ALL CRL-1582 K-562 0,43 HCT-15 20,08 NCI-H441 21,25 CAOV3 0,07 HCT-15 0,06
K-562 Bone
marrow
CCL-243 NCI-H358 0,48 CAOV3 20,02 A-375 21,04 HCT-15 0,08 SW-403 0,11
SK-N-AS Brain CRL-2137 HCT-8 0,48 SW-948 0,09 CAOV3 20,99 SW-948 0,21 C-4II 0,18
BT-20 Breast HTB-19 HCT-15 0,49 A-375 0,22 Hep-3B 20,91 NCI-H441 0,31 NCI-H358 0,22
MCF-7 Breast HTB-22 HT-1080 0,54 NCI-H1993 0,24 C-4I 20,68 NCI-H358 0,33 NCI-H69 0,23
RAJI Burkitt’s L CCL-86 NCI-H441 0,56 NCI-H1650 0,28 SW-620 20,63 SW-620 0,35 WIDR 0,28
C-33A Cervix
Uteri
HTB-31 MCF-7 0,62 NCI-H358 0,30 HT-1080 20,58 SW-480 0,38 CAOV3 0,29
C-4I Cervix Uteri CRL-1594 CAOV3 0,65 C-4II 0,31 HCT-15 20,57 MCF-7 0,39 SNU-449 0,29
C-4II Cervix Uteri CRL-1595 SNU-475 0,65 SW-480 0,39 DMS-79 20,53 HCT-8 0,41 HT-1080 0,29
HCT-15 Colon CCL-225 Hep-3B 0,66 NCI-H661 0,42 C-4II 20,50 A-427 0,41 A-375 0,30
HCT-8 Colon CCL-244 NCI-H1650 0,71 SNU-449 0,43 NCI-H1993 20,45 Hep-3B 0,43 K-562 0,31
SW-403 Colon CCL-230 A-375 0,73 C-4I 0,47 SW-480 20,41 C-4II 0,43 HCT-8 0,34
SW-480 Colon CCL-228 HOS 0,73 K-562 0,48 SHP-77 20,36 NCI-H1650 0,44 NCI-H661 0,36
SW-620 Colon CCL-227 BT-20 0,74 SNU-475 0,50 K-562 20,34 HT-1080 0,51 MCF-7 0,41
SW-948 Colon CCL-237 SHP-77 0,77 MCF-7 0,51 A-427 20,33 NCI-H82 0,51 C-4I 0,41
WIDR Colon CCL-218 CCRF-CEM 0,78 Hep-3B 0,51 HCT-8 20,31 ES-2 0,51 CCRF-CEM 0,43
HT-1080 Fibrosarcoma CCL-121 SNU-449 0,78 CCRF-CEM 0,55 NCI-H358 20,30 CCRF-CEM 0,51 SNU-475 0,47
A-498 Kidney HTB-44 C-4II 0,78 NCI-H69 0,55 SW-403 20,28 SNU-475 0,51 SW-620 0,47
Hep-3B Liver HB-8064 NCI-H1993 0,82 SW-403 0,55 SNU-475 20,28 WIDR 0,53 NCI-H82 0,47
SNU-182 Liver CRL-2235 SW-480 0,82 HOS 0,58 COLO-668 20,25 NCI-H1993 0,54 SW-480 0,48
SNU-423 Liver CRL-2238 C-33A 0,87 HT-1080 0,58 CCRF-CEM 20,19 NCI-H69 0,56 ES-2 0,51
SNU-449 Liver CRL-2234 WIDR 0,88 C-33A 0,59 MOLT-4 20,18 HOS 0,59 NCI-H1993 0,51
SNU-475 Liver CRL-2236 AN3-CA 0,89 AN3-CA 0,60 MCF-7 20,16 SNU-449 0,60 NCI-H441 0,51
A-427 Lung HTB-53 SNU-423 0,90 ES-2 0,61 NCI-H1975 20,14 C-4I 0,61 C-33A 0,53
COLO-668 Lung 87061209 A-498 0,91 SW-620 0,61 SW-948 20,12 MOLT-4 0,61 DMS-79 0,54
DMS-114 Lung CRL-2066 NCI-H661 0,95 BT-20 0,67 SNU-423 20,12 K-562 0,63 SNU-182 0,57
DMS-79 Lung CRL-2049 SW-403 0,96 NCI-H82 0,68 SNU-449 20,11 AN3-CA 0,63 SHP-77 0,64
NCI-H358 Lung CRL-5807 C-4I 0,98 WIDR 0,70 C-33A 20,11 SNU-182 0,66 MOLT-4 0,65
NCI-H441 Lung HTB-174 DMS-114 0,98 MOLT-4 0,73 WIDR 20,11 BT-20 0,66 RAJI 0,65
NCI-H661 Lung HTB-183 RAJI 0,99 A-498 0,73 NCI-H82 20,09 COLO-668 0,71 NCI-H1650 0,67
NCI-H69 Lung HTB-119 SNU-182 1,01 HEC-1-B 0,73 SNU-182 20,08 A-498 0,72 A-427 0,69
NCI-H82 Lung HTB-175 ChaGo-K-1 1,01 SNU-423 0,81 ChaGo-K-1 20,07 SK-N-AS 0,72 BT-20 0,69
SHP-77 Lung CRL-2195 NCI-H82 1,02 NCI-H1975 0,82 RAJI 20,05 RAJI 0,72 AN3-CA 0,71
ChaGO-K-1 Lung HTB-168 MOLT-4 1,03 DMS-79 0,82 BT-20 20,01 NCI-H1975 0,73 SNU-423 0,73
NCI-H1650 Lung CRL-5883 NCI-H69 1,03 RAJI 0,82 DMS-114 0,00 ChaGo-K-1 0,78 NCI-H1975 0,74
NCI-H1975 Lung CRL-5908 ES-2 1,05 ChaGo-K-1 0,83 HOS 0,01 SNU-423 0,80 A-498 0,80
NCI-H1993 Lung CRL-5909 NCI-H1975 1,08 DMS-114 0,89 NCI-H1650 0,14 NCI-H661 0,88 ChaGo-K-1 0,81
RD Muscle CCL-136 SK-N-AS 1,10 SNU-182 0,90 RD 0,20 DMS-79 0,89 HOS 0,87
CAOV3 Ovary HTB-75 A-427 1,10 COLO-668 0,91 SK-N-AS 0,20 SHP-77 0,90 DMS-114 0,93
ES-2 Ovary CRL-1978 RD 1,12 HCT-8 0,95 ES-2 0,21 C-33A 0,91 SK-N-AS 1,04
HOS Sarcoma CRL-1543 COLO-668 1,13 A-427 0,98 HEC-1-B 0,31 DMS-114 0,92 HEC-1-B 1,07
A375 Skin CRL-1619 DMS-79 1,20 SK-N-AS 1,00 NCI-H661 0,32 RD 0,96 RD 1,28
AN3-CA Uterus HTB-111 HEC-1-B 1,31 RD 1,01 A-498 0,49 HEC-1-B 0,98 COLO-668 1,34
HEC-1-B Uterus HTB-113 SW-620 1,31 SHP-77 1,04 AN3-CA 0,61 SW-403 1,08 SW-948 1,45
For each drug, the cell lines are ranked based on their RI values (green: low, red: high, yellow: intermediate RI) at the C2 concentration. The panels of resistant- and
sensitive-designated cell lines are marked by bold and the intermediate cell lines are marked by italic formatting for each agent.
doi:10.1371/journal.pone.0059503.t001
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pre-processing the average of these were computed. As probe sets
with very low abundance are not only unlikely to hold biological
significance, but are also error prone, we made a filtering to retain
only probe sets with an average expression over 100 and maximal
expression over 1000. The complete normalized database is
presented in Table S1.
The complete dataset consisting of the expression profiles has
been arranged into 2 classes, according to the resistance properties
of the cell lines. Intermediate cell lines were excluded. This
selection procedure resulted in 5 datasets, which were treated as
autonomous classification tasks. To obtain the list of genes best
correlated to resistance, we used Significance Analysis of
Microarrays (SAM) [29] and rank products [30,31]. While SAM
is the most widely used method, rank products were found to
deliver the best performance in a setting similar to our project with
low sample size in an earlier summary of available feature selection
methods [32]. The efficacy of the gene sets to discriminate
resistant and sensitive cell lines was computed using Prediction
Analysis of Microarrays [33]. The R file of the used statistical
analysis is available in the supplemental material as Script S1.
To assess the capability of the gene-sets to predict survival, we
searched in Pubmed GEO for datasets with available clinical
follow-up where cancer patients were treated with one of the five
investigated agents. Finally, to search for gene lists similar to our
genes and to identify genes correlated to the identified genes, we
used the CCancer search engine [34].
RNA Isolation and Quality Control
After homogenization using Qiashredder, RNA was isolated
using the Qiagen RNeasy kit (Qiagen, Hilden, Germany)
according to the product user’s guide. Quantity and quality of
the isolated RNA was tested by using a Nanodrop 1000 system
(BCM, Houston, TX, USA) and by gel electrophoresis using an
Agilent Bioanalyzer system (Agilent Technologies Inc., Santa
Clara, CA, USA). RNA (A260) and protein (A280) concentrations
and sample purity (260/280 ratio) were measured. Only high
quality, intact total RNA was accepted for samples which also
showed regular 18S and 28S ribosomal RNA bend pattern on the
Bioanalyzer analysis. RNA was kept at -80uC until RT-PCR
measurement.
TaqMan Assay
TaqMan real-time PCR was used to measure the expression of
95 selected genes (plus one housekeeping gene) using a Micro
Fluidic Card System (Applied Biosystems, Foster City, CA, USA)
in 40 cell lines. The measurements were performed using an ABI
PRISMH 7900HT Sequence Detection System as described in the
products User Guide. The genes were selected to include the top
genes correlated to resistance to the various agents. Additionally,
based on a literature search, a set of genes correlated to targeted
therapy resistance and members of the EGFR/RAS pathway were
also added for additional analyses. The list of included genes is
presented in Table S2.
Data Analysis of the RT-PCR Measurements
For primary data analysis the SDS 2.2 software was used. The
delta Ct values (which represent the expression normalized to
ribosomal 18S expression) were grouped according to the
resistance characteristics against the various agents into groups.
Then, student’s t-test was performed to compare the expression of
the gene in the various groups independently. Statistical signifi-
cance was set at p,0.05.
Renal Cell Carcinoma (RCC) Sample Collection
Patients were treated at the Department of Urology, Semmel-
weis University, Budapest, Hungary between 2005 and 2010.
Samples were collected according to state-of-the-art pathology
protocol from all patients operated for renal cell cancer. However,
only patients with later metastatic disease were included in present
study, as only these patients received a targeted therapy treatment.
The two agents in clinical use for metastatic RCC are sunitinib
and sorafenib. Of these, sunitinib is administered in the first line
setting, thus, these patients were chosen for the immunohisto-
chemical analyses. Tissue microarrays (TMA) of all FFPE samples
were constructed with the Tissue Micro-Array Builder instrument
(Histopathology Ltd., Pe´cs, Hungary). In the TMAs, duplicates of
Figure 1. Overview of the study. Boxes with grey background represent training steps, while white background represents validation steps.
doi:10.1371/journal.pone.0059503.g001
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2 mm wide cores were used of each tumor representing their most
relevant areas according to histopathology.
Immunohistochemistry
The immunohistochemical (IHC) reactions were performed on
4 mm thick sections obtained from TMA blocks. After deparaffi-
nization, the slides were heated in a microwave oven in Target
Retrieval Solution (DAKO, Carpenteria, CA, USA) for 30
minutes. An automated Ventana Benchmark immunostainer
system was used according to the protocol ‘880’ (and ‘870’ for
LGALS8) provided by the manufacturer (Ventana Medical
Systems Inc., Tucson, AZ, USA). RAB17 (dilution, 1:200),
LGALS8 (1:50), EpCam (1:100) and CD9 (1:300) antibodies were
used for staining. The tissues were counterstained with Mayer’s
hemalaun (00-8011, Zymed Laboratories Inc.). Positive controls
and negative control tissues were applied in all IHC runs. In case
of CD9, LGALS8, RAB17 cytoplasmic reaction, for EpCAM
membranous staining was accepted as proper localization.
The stained slides were digitalized with a slide scanner (Mirax
MIDI Scan, 3DHistech Ltd., Budapest, Hungary), and intensity of
the reaction (0: negative reaction, +1: weak positivity, +2:
moderate positivity, +3: strong reaction) and frequency of
positively stained cells (0:0–1%, 1:1–5%, 2:5–10%, 3:10–20%,
4:20–33%, 5:33–50%, 6:50–66%, 7:66–80%, 8:80–100%) were
evaluated separately. Finally, correlation between 25-percentile
survival groups as well as Kaplan-Meier survival plots based on
grouping using the median were computed in WinStat for Excel
(R. Fitch Software, Bad Krozingen, Germany).
Results
Resistance Tests
The resistance of each cell line was measured in triplicates for
each of the three concentrations of the five agents. Then, the cell
lines were ranked based on their RI values. An intermediate RI
value was designated as being within the median RI value +/
210% of the RI range. Cell lines exhibiting higher RIs were
designated as resistant, and cell lines with lower RIs as sensitive. A
complete overview of the separation of cell lines into groups is
depicted in Table 1.
Identification of Discriminatory Genes
For the classification, the genes were filtered to include only
those which achieved an at least 2-fold difference in the average
expression compared between cell lines designated as sensitive or
resistant. Then, feature selection with SAM and rank products was
performed. Only those genes were accepted as significant, which
achieved a false discovery rate below 20%. The complete list of
significant genes is listed in Table S3.
The accuracy of the classification in the leave-one-out cross-
validation setting using all genes in the cell lines resulted in an
efficiency of 92.8% in PAM (cell lines with intermediate resistances
were excluded). The use of the top 100 genes identified by rank
products resulted in 79% correct predictions. The correct
classifications using the top 100 rank products identified genes
are presented in blue and incorrect classifications in red in Table
S4.
Although the investigated agents are in clinical use already for
over 7 years, we were unable to find published data sets suitable
for meta-analysis of the identified gene-set. Thus, we could not
perform an in silico validation on prediction of clinical response or
survival. Using CCancer, all together 27 publications with
overlapping gene sets have been identified. These are presented
in Table S5.
TaqMan Validation of Cell Line-derived Gene Profiles
TaqManq RT-PCR results are summarized in Table 3. 45 of
the 63 genes associated with resistance in the feature selection
using the microarray data were confirmed below p,0.05 and 23
of these below p,0.01. The highest significance was achieved by
ITGB4 (p = 0.005) of the erlotinib-resistance associated, by IADA
(p = 0.003) of the gefitinib-associated genes, by FAT4 (p = 0.011) of
the sorafenib associated genes and by FURIN and ME1 (p = 0.011)
of the lapatinib-associated genes. Several genes were significantly
confirmed of the sunitinib-resistance gene signature including
KRT18 (p = 0.001), LGALS8 (p = 0.019), RAB17 (p = 0.002), CD9
(p = 0.002) and PPL (p = 0.001). Meanwhile, only 7 of the 32 genes
previously described in the literature as associated with resistance
against the targeted therapy agents were confirmed. The complete
normalized result of the TaqMan assays is available as Table S6.
Some of the genes were associated with resistance against
several agents. The highest significance of these was achieved by
COL3A1 (p,0.001 in case of sorafenib-resistance), GJA1 (p,0.001
in case of sunitinib-resistance) and KRT19 (p,0.001 in case of
sunitinib-resistance). We have also depicted the genes associated
with resistance against multiple agents using a circus-plot (see
Figure 2). Using this approach one can recognize the high
number of genes associated with sunitinib resistance and the
presence of only a single gene correlated to lapatinib resistance.
Only two genes (ANXA3 and RAB25) were correlated to intrinsic
resistance against at least four agents.
IHC-based Validation in Renal Cell Carcinomas
Altogether 39 sunitinib-treated patients with metastatic renal
cell carcinoma were included in the study. The patient samples
were collected before the administration of first-line TKI and are
therefore similar to the measurement of gene expression in cell
lines without treatment. The average age of the patients was 59
years, 63% of patients were female. The median overall survival is
14 months with 12/39 deaths. The average survival is 20 months.
Partial metastasectomy was performed in case of seventeen
patients. Representative images of the immunohistochemical
staining for three proteins encoded by the identified genes are
displayed in Figure 3. The detailed results in all samples for all
genes are presented in Table S7.
The increased staining intensity of LGALS8 (p = 0.026) and
RAB17 (p= 0.018) and the frequency of positive cells for EpCAM
(p= 0.01) and LGALS8 (p= 0.01) were correlated to improved
survival. Meanwhile, CD9 - although showing a trend towards
reduced survival in patients having increased staining intensity
Table 2. Concentrations used in the cell lines to measure the
resistance indexes.
Drug Concentration (mM)
C1 C2 C3
lapatinib 2.867 28.67 286.7
sunitinib 0.124 1.24 12.4
sorafenib 1.147 11.47 114.7
erlotinib 0.508 5.08 50.8
gefitinib 0.745 7.45 74.5
doi:10.1371/journal.pone.0059503.t002
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Table 3. Validation of the top genes by TaqMan RT-PCR in the cell lines.
Symbol TaqMan ID Affymetrix ID Gene name p value
Erlotinib
B3GNT3 Hs00429537_m1 204856_at UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 0.021
CAST Hs00156280_m1 208908_s_at calpastatin 0.030
CLMN Hs00226865_m1 221042_s_at calmin (calponin-like, transmembrane) 0.023
ERBB3 Hs00176538_m1 202454_s_at v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 0.016
FXYD5 Hs00204319_m1 218084_x_at FXYD domain containing ion transport regulator 5 0.016
ITGB4 Hs00236216_m1 204990_s_at integrin, beta 4 0.005
LGALS3 Hs00173587_m1 208949_s_at lectin, galactoside-binding, soluble, 3 0.016
NEAT1 Hs01008264_s1 214657_s_at nuclear paraspeckle assembly transcript 1 0.019
PRSS22 Hs00223188_m1 205847_at protease, serine, 22 0.023
S100A10 Hs00741221_m1 200872_at S100 calcium binding protein A10 0.015
SECTM1 Hs00171088_m1 213716_s_at secreted and transmembrane 1 0.026
TFAP2C Hs00231476_m1 205286_at transcription factor AP-2 gamma 0.004
Gefitinib
ADA Hs01110945_m1 216705_s_at adenosine deaminase 0.003
COL5A1 Hs00609088_m1 212489_at collagen, type V, alpha 1 0.018
SLC2A6 Hs01115485_m1 220091_at solute carrier family 2, member 6 0.027
Sorafenib
FAT4 Hs01570491_m1 219427_at FAT tumor suppressor homolog 4 0.011
GNG11 Hs00914578_m1 204115_at guanine nucleotide binding protein (G protein), gamma 11 0.068
TUSC3 Hs00954406_m1 213423_x_at tumor suppressor candidate 3 0.021
Sunitinib
CD9 Hs00233521_m1 201005_at CD9 molecule 0.002
EPCAM Hs00158980_m1 201839_s_at epithelial cell adhesion molecule 0.009
KRT18 Hs01941416_g1 201596_x_at keratin 18 0.001
KRT8 Hs01630795_s1 209008_x_at keratin 8 0.041
LGALS8 Hs00374634_m1 208934_s_at lectin, galactoside-binding, soluble, 8 0.019
LSR Hs00210880_m1 208190_s_at lipolysis stimulated lipoprotein receptor 0.046
PPL Hs00160312_m1 203407_at periplakin 0.001
RAB17 Hs00940833_m1 218931_at RAB17, member RAS oncogene family 0.002
SAT1 Hs00161511_m1 203455_s_at spermidine/spermine N1-acetyltransferase 1 0.003
SIGIRR Hs00222347_m1 52940_at single immunoglobulin and toll-interleukin 1 receptor domain 0.004
Lapatinib
FURIN Hs00965485_g1 201945_at furin (paired basic amino acid cleaving enzyme) 0.011
ME1 Hs00159110_m1 204059_s_at malic enzyme 1, NADP(+)-dependent, cytosolic 0.011
TMOD3 Hs00205710_m1 220800_s_at tropomodulin 3 0.004
Genes associated with resistance against multiple agents
AGR2 Hs00180702_m1 209173_at anterior gradient homolog 2 sunitinib 0.013
ANXA3 Hs00971411_m1 209369_at annexin A3 gefitinib 0.040
sorafenib 0.032
sunitinib 0.001
lapatinib 0.045
CDH1 Hs01023894_m1 201130_s_at cadherin 1, type 1, E-cadherin erlotinib 0.050
sunitinib 0.002
CLDN7 Hs00600772_m1 202790_at claudin 7 sunitinib 0.013
COL3A1 Hs00943809_m1 215076_s_at collagen, type III, alpha 1 gefitinib 0.005
sorafenib 0.000
sunitinib 0.009
FXYD3 Hs00254211_m1 202488_s_at FXYD domain containing ion transport regulator 3 erlotinib 0.037
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(p = 0.14) - was not significant. The Kaplan-Meier survival plot for
EPCAM is depicted in Figure 4.
Discussion
Targeted therapy agents acting via the ERBB/RAS pathway
entered the mainstream cancer therapy guidelines. As still only
10–47% of patients respond to these therapies, it is of utmost
importance to identify the drivers and potential markers of
resistance. In our study we used 45 cancer cell lines and genome-
wide gene expression signatures to identify potential new intrinsic
biomarker genes. As a potential clinical application of our strategy,
we validated the products of resistance-associated genes by IHC
analysis in sunitinib-treated renal cell carcinomas.
We used a heterogeneous panel of cancer cell lines originating
from lung (used TKIs include erlotinib and gefitinib), breast
(lapatinib), renal (sorafenib and sunitinib), and liver (sorafenib).
Cell lines with a known RAS mutation were excluded, since
activating RAS mutations render the inhibition of upstream
tyrosine kinases completely ineffective, as has been previously
shown for colon cancer [35]. The selection of cell lines enables
identification of robust genes related to previously unidentified
independent pathways.
In a recent study of Barretina et al, a large panel of cell lines was
investigated to identify markers of sensitivity against a set of
cytotoxic and targeted agents including three of the tyrosine kinase
inhibitors used in present study (erlotinib, lapatinib and sorafenib)
by measuring sensitivity at the IC50 and EC50 values [36]. To
increase clinical relevance of cancer cell line testing, we used drug
concentrations applied in clinical settings, as we expected to find
the most reliable candidate markers at concentrations also
achievable in patients [37,38]. The robustness of the approach
using such pre-defined clinical concentrations is supported by the
successful validation in a clinical cohort of sunitinib-treated
patients.
We have found most cross-resistance associated genes related to
sunitinib-resistance. Interestingly, so far only a few genes have
been correlated with sunitinib-resistance in the literature while the
number of candidate genes involved in resistance against the other
agents is much larger. Therefore, we particularly focused on
sunitinib resistance and performed immunohistochemical exper-
iments on tumor samples to validate the discriminatory potential
of four new candidate biomarkers, LGALS8, RAB17, EpCAM, and
CD9.
Our first candidate gene LGALS8 encodes a member of the
galectin family. Galectins have been implicated in many functions
including development, differentiation, cell-cell adhesion, cell-
matrix interaction, growth regulation, apoptosis, and RNA
splicing. Galectin-8 may also be involved in angiogenesis [39],
and the expression is changed during hypolaryngeal and laryngeal
tumor progression [40]. The second gene, RAB17 is an epithelial
cell-specific GTPase playing an important role in the regulation of
Table 3. Cont.
Symbol TaqMan ID Affymetrix ID Gene name p value
sunitinib 0.016
GJA1 Hs00748445_s1 201667_at gap junction protein, alpha 1, 43 kDa sunitinib 0.000
KRT19 Hs00761767_s1 201650_at keratin 19 erlotinib 0.032
sorafenib 0.029
sunitinib 0.000
LHX2 Hs00180351_m1 211219_s_at LIM homeobox 2 sorafenib 0.021
MPZL2 Hs00170684_m1 203780_at myelin protein zero-like 2 sorafenib 0.036
sunitinib 0.008
NEFH Hs00606024_m1 33767_at neurofilament, heavy polypeptide erlotinib 0.001
sunitinib 0.002
RAB25 Hs00220628_m1 218186_at RAB25, member RAS oncogene family erlotinib 0.006
gefitinib 0.011
sorafenib 0.015
sunitinib 0.007
S100P Hs00195584_m1 204351_at S100 calcium binding protein P sunitinib 0.024
TACSTD2 Hs00242741_s1 202286_s_at tumor-associated calcium signal transducer 2 sunitinib 0.037
confirmed literature-based genes
ERBB2 Hs01001580_m1 216836_s_at v-erb-b2 oncogene lapatinib 0.034
TGFA Hs00608187_m1 205016_at transforming growth factor, alpha lapatinib 0.034
ANGPT1 Hs00375822_m1 205608_s_at angiopoietin 1 sunitinib 0.036
IFNG Hs00989291_m1 210354_at interferon, gamma sunitinib 0.024
PDGFA Hs00964426_m1 205463_s_at platelet-derived growth factor alpha polypeptide sunitinib 0.044
AKT1 Hs00178289_m1 207163_s_at v-akt murine thymoma viral oncogene homolog 1 erlotinib 0.047
lapatinib 0.041
COX2 Hs00153133_m1 204748_at cyclooxygenase sunitinib 0.034
For the complete results of RT-PCR measurements refer to Table S6.
doi:10.1371/journal.pone.0059503.t003
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membrane trafficking [41]. The third gene, epithelial cell adhesion
molecule (EpCAM) is a membrane protein with proto-oncogenic
properties that is expressed in numerous cancers and is a
promising anticancer drug target. It functions as a homotypic
calcium-independent cell adhesion molecule. The release of the
intracellular domain of the molecule results in the activation of the
WNT pathway [42]. High expression of EpCAM is associated with
poor prognosis in gallbladder carcinoma [43]. Finally, CD9 plays a
role in many cellular processes including differentiation, adhesion,
signal transduction, growth, and in the suppression of cancer cell
motility and metastasis. Miyake et al demonstrated that in patients
with invasive ductal carcinomas the decreased expression of CD9
protein was associated with poor prognosis [44]. The IHC staining
results confirmed the correlations between LGALS8, RAB17 and
EpCAM and survival of renal carcinoma patients treated with
sunitinib, while CD9 failed to achieve significant discriminatory
potential.
According the results of our study these genes might represent
new candidates to identify patients who may benefit from sunitinib
therapy. While the immunohistochemical analysis validated 3 of
the 4 biomarker candidates, a larger clinical study will be needed
to rigorously estimate the power and confirm their clinical
significance.
In the last decade, oncogene addiction has been acknowledged
as one of the key factors of cancer evolution that can also mark
pathways and genes for targeted therapies [45]. However, due to
the adaptation of cancer cells, drug addiction resulting from
intensive treatment can overcome oncogene addiction as has been
recently demonstrated in lung cancer cell lines [46]. To
understand these processes, the identification of genes, which
share a functional role in the resistance against several targeted
therapy agents, is of high priority.
Despite the similar mechanism of action, no gene was identified
to be correlated with the sensitivity against all five agents in our
study. Two genes, ANXA3 and RAB25 were related to four drugs.
Annexin 3 (ANXA3) plays a role in cellular growth and signal
transduction [47], and was previously linked to platinum resistance
in ovarian cancer [48]. The product of the ANXA3 gene was also
identified as one of the tyrosine-phosphorylation targets of EGFR
by immunoprecipitation and western blotting [49]. ANXA3 was
identified as one of the four down-regulated genes involved in
prostate cancer progression in a recent study that compared
EGFR mutated and non-mutated tumours [50]. Our results imply
the possibility of the involvement of ANXA3 in collateral pathways
enabling cancer cells to circumvent TKI therapy.
RAB25 is a member of the RAS oncogene family. Loss of RAB25
was associated with human colorectal adenocarcinomas [51] and
triple-negative breast cancer [52], but the gene has not yet been
investigated in relationship to tyrosine kinase resistance. Future
studies involving patients with simultaneously sequenced tyrosine
kinases and RAS signaling pathway members are needed to assess
its relevance in targeted therapy.
In summary, we present a comprehensive analysis pipeline for
future studies of the investigated tyrosine kinase inhibitors. As a
Figure 2. Circos plot of genes conferring multiple resistances. Circos plot of RT-PCR validated correlations for genes associated with
resistance against multiple agents as identified by microarray analysis. The thickness of the ribbons correlate to the log(p) of the correlation (see
Table 2.). Note the high number of genes associated with sunitinib resistance and the single gene associated with lapatinib resistance. The two most
informative genes are ANXA3 and RAB25, each associated with resistance against four agents.
doi:10.1371/journal.pone.0059503.g002
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Figure 3. Immunohistochemistry. Representative examples of the immunhistochemical validation for CD9, EpCAM and LGALS8. Left column:
normal kidney, right column: selected tumor tissue.
doi:10.1371/journal.pone.0059503.g003
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proof of principle we selected a set of genes associated with
sunitinib resistance (the agent with the least published predictive
biomarkers) for testing in a clinical cohort.
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